Last reviewed 2026-05-28 · How we verify

Bupivacain (Postoperative)

Bupivacain (Postoperative) is a Local anesthetic (amide class) Small molecule drug developed by Başakşehir Çam & Sakura City Hospital. It is currently FDA-approved for Postoperative pain management via local or regional anesthesia, Infiltration anesthesia for surgical procedures. Also known as: Postoperative Fascia Iliaca Compartment Block.

Bupivacaine is a local anesthetic that blocks sodium channels in nerve cell membranes, preventing the initiation and propagation of action potentials.

Bupivacaine is used to manage postoperative pain, as indicated by its use in clinical trials for conditions such as postoperative pain and perioperative complication pain. It is administered via local injection or possibly other methods, as it is also compared to intravenous analgesia in some studies.

At a glance

Mechanism of action

Bupivacaine reversibly inhibits sodium influx into nerve fibers by binding to sodium channels from the intracellular side, thereby stabilizing the neuronal membrane and preventing depolarization. This action blocks conduction of sensory, motor, and autonomic nerve impulses in a dose-dependent manner. When used postoperatively, it provides regional anesthesia and analgesia to reduce pain at the surgical site.

Approved indications

• Postoperative pain management via local or regional anesthesia
• Infiltration anesthesia for surgical procedures

Common side effects

• Systemic toxicity (CNS effects: tremor, seizures)
• Cardiovascular effects (hypotension, arrhythmias)
• Local tissue irritation or injection site reactions
• Allergic reactions (rare with amide anesthetics)

Key clinical trials

• The Efficiency of Periarticular Multimodal Drug Injection in Pain Management Following Primary Unilateral TKA (NA)
• Efficacy of Modified Thoracoabdominal Nerves Block Through Perichondrial Approach in Total Laparoscopic Hysterectomies (NA)
• Comparison Of Clinical Outcomes of Intraperitoneal Bupivacaine Instillation Versus Placebo as Preemptive Analgesia in Patients Undergoing Open Appendectomy (PHASE1)
• Intraoperative Bupivacaine Injection to Reduce Acute and Chronic Pain After TVT/TVT-O Surgery. Randomized Double-Blind Trial (NA)
• Comparison of the Postoperative Analgesic Effects of SPSIPB and TPB in Mastectomy Operations (NA)
• Dexmedetomidine as an Adjuvant to Bupivacaine in Bilateral PECs for Pain Control After Cardiac Surgeries (PHASE4)
• Optimizing Postoperative Pain Control After Laparoscopic Colorectal Surgery (NA)
• Comparison of the Postoperative Analgesic Efficacy of SPSIPB and ISBPB (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Bupivacain (Postoperative) CI brief — competitive landscape report
• Bupivacain (Postoperative) updates RSS · CI watch RSS
• Başakşehir Çam & Sakura City Hospital portfolio CI

Frequently asked questions about Bupivacain (Postoperative)

Related

• Drug class: All Local anesthetic (amide class) drugs
• Target: All drugs targeting Voltage-gated sodium channels
• Manufacturer: Başakşehir Çam & Sakura City Hospital — full pipeline
• Therapeutic area: All drugs in Anesthesia/Pain Management
• Indication: Drugs for Postoperative pain management via local or regional anesthesia
• Indication: Drugs for Infiltration anesthesia for surgical procedures
• Also known as: Postoperative Fascia Iliaca Compartment Block

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing